Arvinas, a clinical-stage biotech company specializing in targeted protein degradation therapies, announced it will participate in a fireside chat at the Jefferies Global Healthcare Conference on November 18, 2026. The company is known for developing PROTAC-based drugs, including the first FDA-approved PROTAC in partnership with Pfizer. Arvinas is advancing multiple drug candidates for cancer and neurodegenerative diseases and will share updates on its clinical programs during the event. A live webcast will be available for investors and the public on the company’s website.
Arvinas presenting at the Jefferies Global Healthcare Conference is the subject, with Pluang's health sector data providing context. For readers following health stocks, as of Nov 11, 2026 19:11 WIB, out of 150 priced US health-sector stocks on Pluang, 67 rose and 75 fell. Among notable movers, Ginkgo Bioworks Holdings Inc (DNA) rose 4.00% to USD 12.49 with a balanced 50% sell/buy order activity and a typical hold time of 9 days, Recursion Pharmaceuticals Inc (RXRX) increased 3.93% to USD 3.70 with 100% buy orders and a longer hold time of 23 days, while Regeneron Pharmaceuticals Inc (REGN) declined 3.61% to USD 883.02 despite 100% buy orders and a much longer hold time of 108 days.
NRx Pharmaceuticals has begun selling a new preservative-free ketamine made in the U.S., addressing a shortage that has persisted since 2018. This ketamine uses innovative blow-fill-seal technology, eliminating the preservative benzethonium chloride,...
FLSmidth & Co. A/S announced its financial calendar for 2027, including key dates for the annual report, interim financial reports, and the annual general meeting. The company emphasizes its commitment to sustainability with its MissionZero goal to a...
Dimensional Fund Advisors Ltd. has filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc, totaling 12,054,886 shares as of November 10, 2026. This disclosure is part of regulatory requirements under the Takeover Code, indicatin...
Dimensional Fund Advisors Ltd. has filed a disclosure showing it holds a 1.61% stake in DCC Energy plc's ordinary shares as of November 10, 2026. The firm sold 42,998 shares recently at a price of £64.5585 each. This disclosure is part of regulatory ...
Novo Nordisk has committed $200 million to the World Diabetes Foundation for 2027–2036 to enhance diabetes prevention and care in low- and middle-income countries. This funding aims to improve equitable access to diabetes services in underserved comm...
